greeksoup/ stocks
Stocks / United States / GILD / Q3 FY2025

Gilead Sciences, Inc. Q3 FY2025 results: revenue $7.8 billion, up 3.0% on the year

Gilead Sciences, Inc. (GILD) reported revenue of $7.8 billion for Q3 FY2025, the quarter ended 30 September 2025, up 3.0% on the same quarter a year earlier. Net income was $3.1 billion, up 143.6% on the year, and diluted earnings per share $2.43. The figures are the company's own, from the 10-Q it filed with the SEC on 7 November 2025.

Revenue$7.8 billionup 3.0%
Net income$3.1 billionup 143.6%
Diluted EPS$2.43
QuarterQ3 FY2025ended 30 September 2025

The quarter, against the one before and a year earlier

LineQ3 FY2025Q2 FY2025Q3 FY2024Change on the year
Revenue7,7697,0827,545+3.0%
Cost of revenue1,5691,5011,574-0.3%
Gross profit6,2005,5815,971+3.8%
Gross margin79.8%78.8%79.1%
Research and development1,3461,4911,395-3.5%
Selling, general and administrative1,3571,3651,433-5.3%
Operating income3,3272,474888+274.7%
Operating margin42.8%34.9%11.8%
Interest expense256254238+7.6%
Pre-tax income3,6412,429956+280.9%
Income tax589468-297n/a
Effective tax rate16.2%19.3%-31.1%
Net income3,0521,9601,253+143.6%
Net margin39.3%27.7%16.6%
Diluted EPS$2.43$1.56$1.00+143.0%

$ million except per share. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.

Cash flow and capital returned

LineQ3 FY2025Q2 FY2025Q3 FY2024Change on the year
Operating cash flow4,1088274,309-4.7%
Capital expenditure147107141+4.3%
Free cash flow3,9617204,168-5.0%
Free cash flow margin51.0%10.2%55.2%
Share-based compensation230225216+6.5%
Buybacks435527300+45.0%
Dividends paid1,005994983+2.2%
Dividend per share$0.79$0.79$0.77+2.6%
Diluted shares, weighted1,254m1,255m1,254m+0.0%
Shares outstanding at period end1,242m1,242m1,246m-0.3%

Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.

Balance sheet at quarter end

LineQ3 FY2025Q2 FY2025Q3 FY2024Change on the year
Total assets58,53355,72154,525+7.4%
Cash and equivalents7,3305,1445,037+45.5%
Receivables5,0954,7814,587+11.1%
Inventory1,7851,8251,869-4.5%
Goodwill8,3148,3148,314+0.0%
Long-term debt24,94124,94623,249+7.3%
Shareholders' equity21,54019,67418,475+16.6%

Quarterly results, the last 12 quarters

Q3 FY2023Q4 FY2023 *Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024 *Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025 *Q1 FY2026Q2 FY2026
Revenue7,0517,1146,6866,9547,5457,5696,6677,0827,7697,9256,9607,803
Cost of revenue1,5652,0901,5521,5441,5741,5811,5401,5011,5691,6241,4451,579
Gross profit5,4865,0245,1345,4105,9715,9885,1275,5816,2006,3015,5156,224
Gross margin78%71%77%78%79%79%77%79%80%80%79%80%
R&D1,4571,4071,5201,3511,3951,6411,3791,4911,3461,5831,3721,764
SG&A1,3151,6071,3751,3771,4331,9061,2581,3651,3571,7941,4511,921
Operating income2,6231,612-4,3222,6448882,4522,2372,4743,3271,9842,586-10,394
Operating margin37%23%-65%38%12%32%34%35%43%25%37%-133%
Interest expense232252254237238248260254256254240247
Pre-tax income2,3181,653-4,4862,0539562,1671,6492,4293,6412,0772,580-10,254
Tax rate6%14%n/a21%-31%18%20%19%16%-5%22%n/a
Net income2,1801,430-4,1701,6141,2531,7831,3151,9603,0522,1832,021-10,496
Net margin31%20%-62%23%17%24%20%28%39%28%29%-135%
Diluted EPS$1.73$1.14-$3.34$1.29$1.00$1.43$1.04$1.56$2.43$1.75$1.61-$8.45
Operating cash flow1,7552,1692,2191,3254,3092,9751,7578274,1083,3272,5443,573
Capital expenditure122215105130141147104107147205117140
Free cash flow1,6331,9542,1141,1954,1682,8281,6537203,9613,1222,4273,433
Buybacks300150400100300350730527435230419355
Dividends paid9539439909729839731,0109941,0059941,0401,029
Shares outstanding1,247m1,246m1,246m1,246m1,246m1,246m1,245m1,242m1,242m1,241m1,242m1,241m
Filing10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q

* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

Source

10-Q for the period ended 30 September 2025, filed 7 November 2025, accession 0000882095-25-000047: the filing on EDGAR. All of Gilead Sciences, Inc.'s filings: EDGAR company page.

The same record on your computer

GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.

Install